Kadmon Holdings, Inc. announced that Tasos G. Konidaris, a member of Kadmon’s board of directors, has been appointed interim chairman, effective immediately. Mr. Konidaris has significant experience in the biotechnology industry, including serving as Executive Vice President and Chief Financial Officer of Alcresta Therapeutics, Inc. since March 2016 and as a senior advisor of Athyrium Capital Management, L.P. since September 2015. Previously, Mr. Konidaris held senior financial and operational roles at Ikaria, Dun & Bradstreet, Schering-Plough, Pharmacia, Rhone-Poulenc Rorer, Novartis and Bristol-Myers Squibb.